ld differ materially from those anticipated in these
forward-looking statements as a result of a variety of factors, including
the risk factors discussed in the Company's periodic reports that are filed
with the Securities and Exchange Commission and available on the SEC's
website (
http://www.sec.gov ). All forward-looking statements attributable
to the Company or persons acting on its behalf are expressly qualified in
their entirety by these risk factors. Other than as required under the
securities laws, the Company does not assume a duty to update these
forward-looking statements.
-- Financial Tables Follow --
YONGYE BIOTECHNOLOGY INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
Yongye The Yongye The
Biotechnology predecessor Biotechnology predecessor
International, Inner International, Inner
Inc. and Mongolia Inc. and Mongolia
Subsidiaries Yongye Subsidiaries Yongye
For Three For Three For Nine For Nine
Months Ended Months Ended Months Ended Months Ended
September 30, September 30, September 30, September
2008 2007 2008 30, 2007
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
Sales $18,202,940 $2,625,137 $45,189,579 $10,752,855
Cost 9,278,944 1,021,719 21,697,964 5,368,480
Gross Profit 8,923,996 1,603,418 23,491,615 5,384,375
Operating Expenses 3,440,036 159,398 7,437,513 230,591
General and
Adminis
'/>"/>
SOURCE Yongye Biotechnology International, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1.
Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference2.
Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.3.
Yongye Biotechnology International Raises $9.4 Million in Private Placement4.
Yongye Biotechnology International Announces Second Quarter Results5.
Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results6.
Yongye Biotechnology International Retains CCG Investor Relations7.
Yongye Biotechnology International, Inc. Appoints New Independent Auditor8.
Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing9.
World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc.10.
InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement11.
InNexus Biotechnology Receives Patent Grants in Europe